This article was originally published in Start Up
Ciblex is developing small molecule drugs to block the export of a group disease-associated proteins which are not secreted in the usual manner ("exported proteins"). Secreted proteins cannot normally be blocked at their source because it is impossible to block an undesireable protein without also blocking all other proteins. Exported proteins, the company believes, can be selectively blocked.
You may also be interested in...
Companies pursuing small-molecule drugs are by far the most popular of the start-ups in biopharmaceuticals. But the biggest opportunity in the business is still up for grabs: the industrialization of medicinal chemistry.
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.
Pain seems as close to a sure bet as the pharmaceutical industry has to offer. Forecasts call for the worldwide analgesic market, already $38 billion in 2002, to grow at a 20% annual clip, nearly doubling to $75 billion by the year 2010. For new drug developers, pain also has the advantage of offering clearly definable endpoints-less pain-and a relatively short duration for clinical trials. No surprise then that more than 200 companies have a hand in developing or marketing pain therapeutics. Among them, the three young companies profiled here-AlgoRx Pharmaceuticals Inc., Algos Therapeutics Inc., and TheraQuest Biosciences LLC.